A tuberculosis (TB) vaccine candidate that has shown modest efficacy rates received a $550 million boost from the Bill and Melinda Gates Foundation (BMGF) and Wellcome Trust, which announced on Tuesday that they will cover its Phase 3 clinical trials. The candidate vaccine, M72, showed modest 54% efficacy in preventing the development of symptomatic TB […] Continue reading ->
The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries.  Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading ->
One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading ->
More R&D into already known emerging disease threats, from Mpox to Lassa fever would go a long way to both bolster developing countries’ preparedness as well as protecting the world, experts argue. Member state negotiations resume next week over a draft WHO convention on pandemic prevention, preparedness and response – which is supposed to be […] Continue reading ->
A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading ->
The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading ->
CAPE TOWN – South Africa’s Health Minister was somewhat embarrassed that his government’s decision to procure pneumococcal vaccines from an Indian company rather than local company Biovac became public during a high-level international meeting on the local production of mRNA vaccines in his country. South Africa’s procurement decision coincided with a meeting in Cape Town […] Continue reading ->